Roflumilast
- TRADE NAMES: Daliresp (Takeda); Daxas (Takeda)
- INDICATIONS: To reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
- CLASS: Anti-inflammatory, Phosphodiesterase inhibitor, Phosphodiesterase type 4 (PDE4) inhibitor
- HALF-LIFE: 17 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Carbamazepine, Cimetidine, Denileukin, Efavirenz, Enoxacin, Erythromycin, Fingolimod, Fluvoxamine, Ketoconazole, Oral Contraceptives, Pazopanib, Phenobarbital, Phenytoin, Pralatrexate, Rifampin
PREGNANCY CATEGORY: C
Contra-indicated in patients with moderate to severe liver impairment (Child-Pugh B or C class).
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of roflumilast in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
